Sign in →

Test Code WASEQ Alpha Globin Gene Sequencing, Varies

Useful For

Diagnosing nondeletional alpha thalassemia

 

Testing for nondeletional alpha thalassemia in a symptomatic individual

 

Follow-up testing to an abnormal hemoglobin electrophoresis that identified an alpha-globin chain variant

Method Name

Polymerase Chain Reaction (PCR)/ Sanger Sequencing

Reporting Name

Alpha Globin Gene Sequencing, B

Specimen Type

Varies


Ordering Guidance


For first-tier testing for alpha thalassemia detection, order THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Serum and Whole Blood.

 

For first-tier testing for an alpha-globin variant, order HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood.

 

If genetic testing is desired, the first-tier genetic test assesses large deletional alpha-thalassemia alterations. Order ATHAL / Alpha-Globin Gene Analysis, Varies.



Necessary Information


1. Patient's age is required.

2. Include recent transfusion information.



Specimen Required


Submit only 1 of the following specimens:

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD), green top (sodium heparin)

Specimen Volume: 4 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in the original tube. Do not aliquot

Specimen Stability Information: Refrigerate 30 days(preferred)/Ambient 14 days

 

Specimen Type: Extracted DNA from whole blood

Container/Tube: 1.5- to 2-mL tube

Specimen Volume: Entire specimen

Collection Instructions:

1. Label specimen as extracted DNA and source of specimen

2. Provide volume and concentration of the DNA

Specimen Stability Information: Frozen (preferred)/Refrigerate/Ambient


Specimen Minimum Volume

Blood: 1 mL
Extracted DNA: 50 mcL at 50 ng/mcL concentration

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

Gross hemolysis OK
Moderately to severely clotted Reject

Clinical Information

Alpha-globin gene sequencing detects alpha-globin variants and nondeletional alpha-thalassemia variants.

 

Alpha thalassemia is the most common monogenic condition in the world. It is estimated that up to 5% of the world's population carries at least one alpha-thalassemia variant and, in the United States, approximately 30% of African Americans are thought to carry an alpha-thalassemia variant. Alpha-thalassemia variations are most common in individuals of Southeastern Asian, African, Mediterranean, Indian, and Middle Eastern descent, but they can be found in persons from any ethnic group.

 

Four alpha-globin genes are normally present, 2 copies on each chromosome 16. Alpha-thalassemia variants result in decreased alpha-globin chain production. In general, alpha thalassemia is characterized by hypochromic, microcytic anemia and varies clinically from asymptomatic (alpha-thalassemia silent carrier and alpha-thalassemia trait) to lethal hemolytic anemia (hemoglobin [Hb] Barts hydrops fetalis).

 

Large deletions of the alpha-globin genes account for approximately 90% of alpha-thalassemia alterations, and these variations will not be detected by alpha-globin gene sequencing. Other variants, such as point alterations or small deletions within the alpha-globin genes, account for most of the remaining 10% of alpha-thalassemia variations. These nondeletional subtypes can be detected by alpha-globin gene sequencing. The most common nondeletional alpha-thalassemia variant is Hb Constant Spring.

 

The majority of alpha-globin chain variants are clinically and hematologically benign however, some cause erythrocytosis and chronic hemolytic anemia. Hemoglobin electrophoresis may not be able to confirm their identity. In these instances, alpha-globin gene sequencing can be useful.

Reference Values

An interpretive report will be provided.

Day(s) Performed

Monday through Friday

Report Available

10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81259-HBA1/HBA2; full sequence

Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. Metabolic Hematology Patient Information (T810)

3. If not ordering electronically, complete, print, and send Benign Hematology Test Request Form (T755) with the specimen